Abiomed Inc (ABMD)
$176.51 6.87 (4.05%)
16:41 EDT ABMD Stock Quote Delayed 15 Minutes
Previous Close $176.51
Market Cap 7.85B
PE Ratio 72.04
Volume (Avg. Vol.) 814,700
Day's Range 169.30 - 177.50
52-Week Range 155.02 - 427.70
Dividend & Yield N/A (N/A)
ABMD Stock Predictions, Articles, and Abiomed Inc News
- From InvestorPlace
- From the Web
These 7 growth stocks remain positioned for significant future increases, and could bring huge returns to new investors for years to come.
These beaten-down healthcare stocks still have plenty of long-term potential. Here's what investors need to know about each.
The market is climbing a wall of worry. Here are 10 triple-A stocks I recommend to help you profit from the strength.
The markets may be volatile but the trends for these tech stocks are strong.
The tech wreck failed to sink these five companies, making them some of the best stocks to buy in 2018. But can they continue their strength in 2019?
When considering medical devices stocks to buy, consider companies with FDA-approved devices, growing sales and overall financial strength.
These tech stocks prove that there’s plenty of growth out there, if you know where to look. Here's what investors need to know about each.
Medical device stocks could be the best play in all of healthcare. Here are five of the best choices for any portfolio.
Each case for these momentum stocks is backed by Wall Street's top analysts and the stocks should continue to power through 2018 and beyond.
Niche medical device maker Abiomed has plenty of heart for growth. ABMD stock isn't the sexiest play, but it's well worth a look.
Abiomed stock is down 10 percent following first-quarter earnings. The company exceeded expectations and reported growth in the triple digits. So what gives? The good news is priced in.
If you're looking for some stellar stocks to buy, these 7 A-rated stocks are worth a look from any investor.
Bitcoin may look attractive, but there are stocks to buy with growth potential that you don't have to worry about going broke to own.
From Market News Video
The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO
Navellier RatingsPowered by Portfolio Grader
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!